Teriparatide Treatment Increases Hounsfield Units in the Thoracic Spine, Lumbar Spine, Sacrum, and Ilium Out of Proportion to the Cervical Spine.
Journal
Clinical spine surgery
ISSN: 2380-0194
Titre abrégé: Clin Spine Surg
Pays: United States
ID NLM: 101675083
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
received:
20
02
2020
accepted:
14
04
2021
pubmed:
25
5
2021
medline:
26
10
2021
entrez:
24
5
2021
Statut:
ppublish
Résumé
This was a retrospective chart review. The objective of this study was to compare the effect of teriparatide on Hounsfield Units (HU) in the cervical spine, thoracic spine, lumbar spine, sacrum, and pelvis. Second, to correlate HU changes at each spinal level with bone mineral density (BMD) on dual-energy x-ray absorptiometry (DXA). HU represent a method to estimate BMD and can be used either separately or in conjunction with BMD from DXA. A retrospective chart review included patients who had been treated with at least 6 months of teriparatide. HU were measured in the vertebral bodies of the cervical, thoracic, and lumbosacral spine and iliac crests. Lumbar and femoral neck BMD as measured on DXA was collected when available. One hundred twenty-five patients were identified for analysis with an average age of 67 years who underwent a mean (±SD) of 22±8 months of teriparatide therapy. HU improvement in the cervical spine was 11% (P=0.19), 25% in the thoracic spine (P=0.002), 23% in the lumbar spine (P=0.027), 17% in the sacrum (P=0.11), and 29% in the iliac crests (P=0.09). Lumbar HU correlated better than cervical HU with BMD as measured on DXA. Teriparatide increased average HU in the thoracolumbar spine to a proportionally greater extent than the cervical spine. The cervical spine had a higher baseline starting HU than the thoracolumbar spine. Lumbar HU correlated better than cervical and thoracic HU with BMD as measured on DXA.
Sections du résumé
STUDY DESIGN
This was a retrospective chart review.
OBJECTIVE
The objective of this study was to compare the effect of teriparatide on Hounsfield Units (HU) in the cervical spine, thoracic spine, lumbar spine, sacrum, and pelvis. Second, to correlate HU changes at each spinal level with bone mineral density (BMD) on dual-energy x-ray absorptiometry (DXA).
SUMMARY OF BACKGROUND DATA
HU represent a method to estimate BMD and can be used either separately or in conjunction with BMD from DXA.
MATERIALS AND METHODS
A retrospective chart review included patients who had been treated with at least 6 months of teriparatide. HU were measured in the vertebral bodies of the cervical, thoracic, and lumbosacral spine and iliac crests. Lumbar and femoral neck BMD as measured on DXA was collected when available.
RESULTS
One hundred twenty-five patients were identified for analysis with an average age of 67 years who underwent a mean (±SD) of 22±8 months of teriparatide therapy. HU improvement in the cervical spine was 11% (P=0.19), 25% in the thoracic spine (P=0.002), 23% in the lumbar spine (P=0.027), 17% in the sacrum (P=0.11), and 29% in the iliac crests (P=0.09). Lumbar HU correlated better than cervical HU with BMD as measured on DXA.
CONCLUSIONS
Teriparatide increased average HU in the thoracolumbar spine to a proportionally greater extent than the cervical spine. The cervical spine had a higher baseline starting HU than the thoracolumbar spine. Lumbar HU correlated better than cervical and thoracic HU with BMD as measured on DXA.
Identifiants
pubmed: 34029261
doi: 10.1097/BSD.0000000000001203
pii: 01933606-202108000-00006
doi:
Substances chimiques
Teriparatide
10T9CSU89I
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
E370-E376Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
J.L.F. reports being a consultant to Medtronic. A.S.S. reports being a consultant to Johnson & Johnson. B.L.C. reports receiving royalties from DePuy Synthes, Zimmer Biomet, and Wolters Kluwer, and receiving institutional support for a spine fellowship from AOSNA. B.D.E. is a consultant for Johnson & Johnson, reports receiving the support of non–study-related clinical or research effort from SI Bone and being on the scientific advisory board of Injectsense. The remaining authors declare no conflict of interest.
Références
Chin DK, Park JY, Yoon YS, et al. Prevalence of osteoporosis in patients requiring spine surgery: incidence and significance of osteoporosis in spine disease. Osteoporos Int. 2007;18:1219–1224.
Wagner SC, Formby PM, Helgeson MD, et al. Diagnosing the undiagnosed: osteoporosis in patients undergoing lumbar fusion. Spine (Phila Pa 1976). 2016;41:E1279–E1283.
Anderson PA, Jeray KJ, Lane JM, et al. Bone health optimization: beyond own the bone: AOA critical issues. J Bone Joint Surg Am. 2019;101:1413–1419.
Orwig DL, Chiles N, Jones M, et al. Osteoporosis in men: update 2011. Rheum Dis Clin North Am. 2011;37:401–414; vi.
Adler RA. Osteoporosis in men: what has changed? Curr Osteoporos Rep. 2011;9:31–35.
Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–1259.
Zaidi Q, Danisa OA, Cheng W. Measurement techniques and utility of Hounsfield Unit values for assessment of bone quality prior to spinal instrumentation: a review of current literature. Spine (Phila Pa 1976). 2019;44:E239–E244.
Hendrickson NR, Pickhardt PJ, Del Rio AM, et al. Bone mineral density T-scores derived from CT attenuation numbers (Hounsfield Units): clinical utility and correlation with dual-energy X-ray absorptiometry. Iowa Orthop J. 2018;38:25–31.
Schreiber JJ, Anderson PA, Rosas HG, et al. Hounsfield Units for assessing bone mineral density and strength: a tool for osteoporosis management. J Bone Joint Surg Am. 2011;93:1057–1063.
Pickhardt PJ, Pooler BD, Lauder T, et al. Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications. Ann Intern Med. 2013;158:588–595.
Lee SJ, Binkley N, Lubner MG, et al. Opportunistic screening for osteoporosis using the sagittal reconstruction from routine abdominal CT for combined assessment of vertebral fractures and density. Osteoporos Int. 2016;27:1131–1136.
Fischer CR, Hanson G, Eller M, et al. A systematic review of treatment strategies for degenerative lumbar spine fusion surgery in patients with osteoporosis. Geriatr Orthop Surg Rehabil. 2016;7:188–196.
Genant HK, Engelke K, Bolognese MA, et al. Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32:181–187.
Kleerekoper M, Greenspan SL, Lewiecki EM, et al. Assessing the effects of teriparatide treatment on bone mineral density, bone microarchitecture, and bone strength. J Bone Joint Surg Am. 2014;96:e90.
Miyauchi A, Matsumoto T, Sugimoto T, et al. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone. 2010;47:493–502.
Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008;23:1591–1600.
McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165:1762–1768.
Senn C, Gunther B, Popp AW, et al. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int. 2014;25:1945–1951.
Saag KG, Agnusdei D, Hans D, et al. Trabecular bone score in patients with chronic glucocorticoid therapy-induced osteoporosis treated with alendronate or teriparatide. Arthritis Rheumatol. 2016;68:2122–2128.
Ohtori S, Inoue G, Orita S, et al. Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine (Phila Pa 1976). 2012;37:E1464–E1468.
Mikula A, Puffer R, St. Jeor J, et al. Teriparatide treatment increases Hounsfield Units in the lumbar spine out of proportion to DEXA changes. J Neurosurg Spine. 2020;32:50–55.
Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18:1932–1941.
Paggiosi MA, Yang L, Blackwell D, et al. Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study. Osteoporos Int. 2018;29:1367–1378.
Colantonio DF, Saxena SK, Vanier A, et al. Cervical spine computed tomography Hounsfield Units accurately predict low bone mineral density of the femoral neck. Clin Spine Surg. 2020;33:E58–E62.
Chaudhary N, Lee JS, Wu JY, et al. Evidence for use of teriparatide in spinal fusion surgery in osteoporotic patients. World Neurosurg. 2017;100:551–556.
Ohtori S, Inoue G, Orita S, et al. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976). 2013;38:E487–E492.
Inoue G, Ueno M, Nakazawa T, et al. Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. J Neurosurg Spine. 2014;21:425–431.
Kaliya-Perumal AK, Lu ML, Luo CA, et al. Retrospective radiological outcome analysis following teriparatide use in elderly patients undergoing multilevel instrumented lumbar fusion surgery. Medicine (Baltimore). 2017;96:e5996.
Yagi M, Ohne H, Konomi T, et al. Teriparatide improves volumetric bone mineral density and fine bone structure in the UIV+1 vertebra, and reduces bone failure type PJK after surgery for adult spinal deformity. Osteoporos Int. 2016;27:3495–3502.
Leder BZ, Neer RM, Wyland JJ, et al. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009;94:2915–2921.
Eastell R, Mitlak BH, Wang Y, et al. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. Osteoporos Int. 2019;30:667–673.
Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int. 2004;15:992–997.
Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res. 2009;24:726–736.